Quick Answer
Coconut Oil Cognition Meta-Analysis has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: EK supplementation was associated with a statistically significant improvement in cognitive performance compared with placebo (SMD = 0.29, 95% CI 0.16-0.41; p p = 0.083), study duration (acute vs.
Key Takeaways
- 01EK supplementation was associated with a statistically significant improvement in cognitive performance compared with placebo (SMD = 0.29, 95% CI 0.16-0.41; p p = 0.083), study duration (acute vs. [Bonnechère B (2026)]
- 02Discussion EK supplementation is associated with modest improvements in cognitive performance across diverse populations and study designs. [Bonnechère B (2026)]
- 03Introduction Cognitive function is closely linked to brain energy metabolism and may be compromised by aging, metabolic stress, and neuropsychiatric disease. [Bonnechère B (2026)]
- 04Ketone bodies can serve as an alternative cerebral fuel and may also exert signaling effects relevant to cognition. [Bonnechère B (2026)]
The current Migaku evidence database contains 2 reusable source documents for Coconut Oil Cognition Meta-Analysis. This answer focuses on strength of evidence and what the studies can or cannot prove.
- EK supplementation was associated with a statistically significant improvement in cognitive performance compared with placebo (SMD = 0.29, 95% CI 0.16-0.41; p p = 0.083), study duration (acute vs. [Bonnechère B (2026); evidence level 1]
- Discussion EK supplementation is associated with modest improvements in cognitive performance across diverse populations and study designs. [Bonnechère B (2026); evidence level 1]
- Introduction Cognitive function is closely linked to brain energy metabolism and may be compromised by aging, metabolic stress, and neuropsychiatric disease. [Bonnechère B (2026); evidence level 1]
- Ketone bodies can serve as an alternative cerebral fuel and may also exert signaling effects relevant to cognition. [Bonnechère B (2026); evidence level 1]
- 1 2 3 4 Diet is crucial in preventing cardiometabolic diseases (CMD), defined as obesity, type 2 diabetes (T2D), and cardiovascular disease (CVD), which now more broadly includes chronic kidney disease [] and metabolic dysfunction-associated steatotic liver disease. [Astrup Arne (2026); evidence level 4]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources